济南不能勃起济南治早泻的吗,济南早泄一般治疗,济南前列腺钙化治疗方法,济南出现勃起不坚怎么办,济南性功能障碍去医院看哪个科,济南勃起不久就软了,济南早泄中医可以治疗

LOS ANGELES, June 5 (Xinhua) -- U.S. researchers have developed two new drugs that can prolong the lives of patients with advanced melanoma, it was announced on Sunday.Research on both drugs was presented at the on-going annual meeting of the American Society of Clinical Oncology in Chicago, according to HealthDay News.This is the first big news in years for treatment of melanoma, one of the deadliest forms of skin cancer and one that is notoriously difficult to treat, let alone cure, the report said.The first treatment, vemurafenib, inhibits a gene mutation harbored in half of all melanoma patients, but is not yet approved by the U.S. Food and Drug Administration.The other drug, Yervoy (ipilumumab), is an immune system therapy that won approval in March."The March FDA approval of ipilumumab (Yervoy) was the first new drug approval for melanoma in 13 years," said Tim Turnham, executive director of the Melanoma Research Foundation.The two drugs were developed by researchers at Memorial Sloan- Kettering Cancer Center in New York City, the report said."This is really a huge step toward personalized care in melanoma," Dr. Paul Chapman, lead author of the first study and the attending physician in the melanoma/sarcoma service at Memorial Sloan-Kettering, said in a statement. "This (vemurafenib) is the first successful melanoma treatment tailored to patients who carry a specific gene mutation in their tumor, and could eventually become one of only two drugs available that improves overall survival in advanced cancers.""Having two trials that show a benefit in survival in patients with melanoma, both of these in first-line settings -- we weren't here just a few years ago," said Dr. Stephen Hodi, director of the Melanoma Center at Dana Farber Cancer Institute in Boston. "These are huge, paradigm-shifting results for the field."In the vemurafenib trial, sponsored by the drug's makers, researchers randomly assigned 675 patients with advanced, inoperable melanoma to receive either the chemotherapy drug dacarbazine or vemurafenib. Vemurafenib targets the V600E mutation in the BRAF gene.At the three-month mark, patients taking vemurafenib were 63 percent less likely to die and 74 percent less likely to die or see their cancer return, compared to patients taking dacarbazine alone.Few patients had side effects in the vemurafenib group, although some did develop squamous cell carcinoma, a less dangerous form of skin cancer.This is the first drug that has been proven superior to chemotherapy in this group of hard-to-treat patients, the researchers said."There was such a substantial benefit that we recommended that patients cross over," Chapman said at a Sunday news briefing. "It' s unprecedented to report a trial this early. The median follow-up time was three months." Yet the differences between the two groups became evident almost immediately.Dr. Lynn Schuchter, co-moderator of the briefing and division chief of hematology-oncology at Abramson Cancer Center of the University of Pennsylvania in Philadelphia, said symptoms subsided in some patients almost immediately, enabling them to cut back on pain medication in just 72 hours."The median time to progression with dacarbazine was 1.6 months versus three months with vemurafenib, which is a huge difference," said Chapman.In the second study, about 500 patients were randomly picked to receive Yervoy plus dacarbazine or dacarbazine alone.Those taking both drugs lived a median of 11.2 months compared to 9.1 months for those taking dacarbazine alone. Time to recurrence of disease was about the same for both groups: 2.8 months and 2.6 months, respectively.Almost half of those taking the combination therapy were alive after one year, compared to 36.3 percent in the other group. After two years, the rates were 28.5 percent and 17.9 percent, respectively.By three years out, 20.8 percent of those in the combination group were alive compared with 12.2 percent of those taking chemotherapy alone.This is the first study to combine chemotherapy and immunotherapy both safely and effectively.A study to test vemurafenib in combination with Yervoy has already begun, according to HealthDay News.

TAMPA, the United States, June 18 (Xinhua) -- The HIV/AIDS patients in the U.S. state of Florida are in dispute with state authorities over a proposal to impose tighter restrictions on those who qualify for drugs provided by the state's AIDS Drug Assistance Program (ADAP).According to the proposed restrictions, individuals would have to earn less than 21,000 U.S. dollars annually to qualify for ADAP drugs. If approved by the Florida Department of Health (FDH), this would affect approximately 1,150 HIV/AIDS patients."The FDH is currently looking at the number of cost containment activities, including altering the financial eligibility for ADAP services," said FDH's press secretary Jessica Hammonds. "After soliciting public input on this matter, the department is in the final stages of evaluating the matter."The Florida ADAP program serves almost 9,500 clients, each of whom receiving 8,600 dollars in funding annually, Hammonds said. There are still another 3,482 on a waiting list.Four FDH sponsored public hearings were held in April and May on the proposal to reduce HIV/AIDS funding. Two were held in Miami, one in Tampa, and the other one was held in the state capital city of Tallahassee. Over 1,000 people attended the hearings.The issue has become so ubiquitous that it caught the attention of the Elton John AIDS Foundation (EJAF), created by the popular entertainer of the same name.

SAN FRANCISCO, June 28 (Xinhua) -- Google has launched a new site wdyl.com, a search service standing for "what do you love" and integrating a variety of Google's search products on one page.According to a report by technology blog TechCrunch, wdyl.com was quietly rolled out several days ago and the formal launch was set for Monday, but engineering issues have been holding it back until early Tuesday morning.The site can return users a single page of relevant results across a variety of Google's search services for whatever query is typed into the search box, whose search button is even a heart.For example, after typing in "pasta," several columns appear on the search results page, allowing users to see images of pasta, watch videos of pasta, or browse latest news about pasta.Other search results include pasta-related maps, books, blogs, patents, translation, popularity on the web and etc.

WELLINGTON, May 31 (Xinhua) -- New Zealand agricultural produce regulators cleared an Auckland-based firm that exported infant formula to China of food safety concerns, just hours after confirming they had launched an investigation.The clarification came the same day Kiaora New Zealand International, marketers of Heitiki infant formula, apologized for using a Maori name and icon on its product packaging.The Ministry of Agriculture and Forestry (MAF) issued a statement Tuesday to say Kiaora New Zealand had been cleared of food safety and export regulations concerns, but an investigation into the labeling and marketing of Heitiki would continue.The MAF issued a statement earlier Tuesday confirming reports it was investigating the product's safety, but MAF compliance and enforcement director Geoff Allen said in a later statement the investigation had been underway for about 10 days."The investigation was triggered by our internal surveillance. The investigation was primarily on whether there was a food safety issue, and I'm pleased to report that no food safety issues were identified," said Allen.Nothing "untoward" was identified in the origin and export destination of Heitiki-branded products, which were manufactured in New Zealand according to legal requirements, said Allen."The investigation has now turned to the labeling and marketing of the product. This aspect is ongoing, and seeks to identify anything in the labeling or marketing that is inaccurate or misleading.

SAN FRANCISCO, June 6 (Xinhua) -- Apple's chief executive officer Steve Jobs on Monday took a break from his medical leave to introduce the company's new cloud-based service iCloud.Jobs, in his trademark black turtleneck and jeans, got a standing ovation in San Francisco's Moscone Center when he appeared on stage. Someone screamed "I love you," and Jobs said " it always helps and I appreciated it.""ICloud stores your content in the cloud and wirelessly pushes it to all your devices," said Jobs, calling it Apple's "next big insight."According to Apple, iCloud Backup will automatically back up users' iOS devices to iCloud daily over Wi-Fi when they charge their iPhone, iPad or iPod touch. Backup content includes purchased music, apps, camera roll, device settings and app data. It will also automatically upload documents from iWork in the cloud and pushes them to users' all relevant devices.The service will currently be free and replaces the former MobileMe which Apple once charged 99 U.S. dollars per year.Users will get five gigabytes of memory which is not counting purchased apps, music or books. A beta version is available on Monday and the final version will be shipping with iOS 5 this fall, with paid plans for more storage to be announced at that time.For a 24.99-dollar paid music plan named iTunes Match, a user's iTunes library will be scanned and they will gain instant access to those tracks or albums from compatible devices, rather than uploading them. Song files, including those converted from CDs, will also be uploaded to iCloud if they are not matched in iTunes stores but recognized by music labels.Jobs pointed out that iTunes Match paid plan is cheaper than Amazon's offering and Google has not announced a price yet, saying "it's an industry leading effort."The Apple CEO finally showed a photo of the company's new, massive data center in North Carolina to emphasize Apple is ready for iCloud service.Before Jobs, Apple executives introduced Lion, the eighth major release of Mac OS X and iOS 5, the next version of Apple's mobile operating system.Phil Schiller, Apple's marketing chief and Craig Federighi, the OS X software vice president, introduced ten key new features among the 250 ones of the new Mac operating system, including multi-touch features that bring the users experience on iPhone to their computers.Lion will be available to customers in July in Mac App Store. The price is adjusted to 29.99 dollars from 129 dollars Apple used to charge for upgrades.Scott Forstall, head of Apple's iOS software, demoed Apple's new mobile operating system, noting that iOS already has 44 percent of the mobile operating system market.The new version iOS 5 will have more than 200 new features, including a Notification Center that catches missed calls, mail messages and phone messages; and a feature called Reminder that provides virtual Post-it notes using geolocation technology.The new mobile operating system also integrates Twitter with many other iPhone apps and has a Newsstand on which the newspaper and magazines icons will be the actual covers of the publications.Apple said that iOS 5 is coming to the public this fall, which probably means the new iPhone is coming in the fall as well.Apple's new services are unveiled at its annual Worldwide Developers Conference (WWDC). Jobs kicked off the keynote event by saying that Apple had sold out 5,200 tickets to attendees just in two hours.